CERo Therapeutics Holdings, Inc. (NASDAQ:CERO – Get Free Report) major shareholder Bioventures Opportunities G. Yk sold 1,343,801 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $0.08, for a total transaction of $107,504.08. Following the completion of the sale, the insider now directly owns 17,618,618 shares of the company’s stock, valued at $1,409,489.44. This trade represents a 7.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
CERo Therapeutics Price Performance
Shares of CERO stock traded down $0.01 on Friday, hitting $0.06. The stock had a trading volume of 31,185,395 shares, compared to its average volume of 20,494,506. CERo Therapeutics Holdings, Inc. has a 52-week low of $0.06 and a 52-week high of $12.80. The stock’s 50 day moving average is $0.13 and its 200-day moving average is $0.22.
CERo Therapeutics Company Profile
Featured Stories
- Five stocks we like better than CERo Therapeutics
- Stock Sentiment Analysis: How it Works
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for CERo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CERo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.